Inc. took a nosedive today, dropping around 20% after the company announced results from the Phase 2 study of its ...

Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...

Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...

Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.

Biotech stocks Viking Therapeutics (VKTX) and Intellia Therapeutics (NTLA are both making outsized moves today ...

Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach ...

Consider these two companies: Block ( SQ 0.01%) and Intellia Therapeutics ( NTLA -2.13%). Both are among picks by Cathie Wood ...

JonesTrading analyst Debanjana Chatterjee has assigned their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...

A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...

Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass ...